CML results from expression of the constitutively active tyrosine kinase Bcr-Abl, a fusion of the breakpoint cluster region (Bcr) protein and the kinase domain of Abl (Abl kinase). The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.